Paper Details
- Home
- Paper Details
[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
Author: BottaD, Gaudy-MarquesteC, GrobJ-J, LorcyS, ManciniJ, OuliesV, PortalI, QuilesN, RichardM-A
Original Abstract of the Article :
BACKGROUND: Telaprevir, sale of which was suspended, has been approved in combination with pegylated interferon and ribavirin (triple therapy) in the treatment of chronic hepatitis C virus (HCV). Skin eruptions and isolated cases of severe cutaneous adverse reactions (SCAR) have been reported. AIMS...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.annder.2016.02.028
データ提供:米国国立医学図書館(NLM)
Telaprevir: Navigating the Skin Side Effects
The desert of chronic hepatitis C (HCV) treatment can be a challenging one, with patients navigating the complexities of therapy and potential side effects. This study investigates the incidence and characteristics of cutaneous adverse events (AEs) associated with telaprevir, a drug used in combination therapy for HCV.
A Rough Patch on the Road to Recovery
The study highlights the high incidence of skin eruptions associated with telaprevir, but emphasizes that most are mild in intensity. However, the authors acknowledge the potential for severe cutaneous adverse reactions (SCARs), underscoring the need for careful monitoring and prompt intervention. It's like encountering a patch of rough terrain on a desert journey – vigilance and adaptability are essential for navigating safely.
Managing the Journey
This research emphasizes the importance of close dermatological follow-up for patients receiving telaprevir therapy. The authors recommend early detection and management of skin AEs to minimize the risk of severe complications. This approach ensures a smoother and safer journey through the desert of HCV treatment.
Dr.Camel's Conclusion
This research shines a light on the importance of managing the potential side effects of HCV therapies. Like a skilled desert guide, clinicians must be aware of the potential challenges and prepare patients for a successful journey toward recovery.
Date :
- Date Completed 2017-06-14
- Date Revised 2018-12-02
Further Info :
Related Literature
French
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.